Featured Clinical Trials
Learn what’s coming down the research pipeline, and find breast cancer clinical trials you may be eligible to participate in.
Postmenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer that continued to grow during or after treatment with an aromatase inhibitor (anastrozole, letrozole, and exemestane) are needed for a clinical trial. Researchers conducting the trial are examining the safety and effectiveness of combining the PI3K inhibitor BMK120 with fulvestrant (Faslodex).
Baltimore-based researchers seek participants with metastatic breast cancer for a phase II trial comparing a combination of chemotherapy plus a cancer vaccine with or without trastuzumab.
Researchers are recruiting 700 women with HER2-negative breast cancer for an international clinical trail assessing disease-free survival (DFS), the length of time during which participants show no signs of cancer, when treated with NeuVax, a cancer vaccine designed to prevent or delay disease recurrence.
A study for women with early-stage breast cancer removed by lumpectomy compares the safety and effectiveness of a more rapid course of radiation with standard therapy.
Researchers seek women with metastatic, HER2 positive breast cancer for a clinical trial that will test a new combination treatment.
Researchers seek women with ER positive, HER2 negative metastatic breast cancer for a clinical trial that will test letrozole in combination with a new medicine.
A clinical trial seeks 880 participants to test whether removing the tumor in the breast in newly diagnosed metastatic breast cancer helps women who receive systemic therapy to live longer than those who receive systemic therapy alone.
The new SystHERs (Systematic Therapies for HER2 positive Metastatic Breast Cancer Study) Registry seeks to enroll 1,000 people with HER2 positive metastatic breast cancer to analyze treatment patterns and outcomes.
Researchers seek 4,000 participants for a clinical trial that will study whether hormonal therapy alone is adequate treatment for early-stage invasive breast cancer that traveled to one to three axillary lymph nodes and is found to be of low or intermediate risk for recurrence by genomic tests.
A research study on immune response and suppression in different types of breast cancer seeks women diagnosed between the ages of 18 and 49 anywhere in the U.S.